Comparative retinal vessel size study of intravitreal ranibizumab and bevacizumab in eyes with neovascular age-related macular degeneration

KURT M. M., Çekiç O., Akpolat Ç., Aslankurt M., Elçioǧlu M. N.

Ophthalmologica, cilt.238, sa.3, ss.147-153, 2017 (SCI-Expanded, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 238 Sayı: 3
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1159/000477180
  • Dergi Adı: Ophthalmologica
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.147-153
  • Anahtar Kelimeler: Bevacizumab, Neovascular age-related macular degeneration, Ranibizumab, Retinal vessel diameter
  • Samsun Üniversitesi Adresli: Hayır

Özet

Purpose: The aim of this paper was to assess and compare the effects of intravitreal ranibizumab and bevacizumab on retinal vessel diameter in eyes with neovascular age-related macular degeneration (AMD). Methods: Patients with neovascular AMD who underwent intravitreal injection of either ranibizumab or bevacizumab were included. Noninjected fellow eyes served as a control. The main outcome measures were central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and the artery-vein ratio (AVR). Results: In the ranibizumab group, the mean CRAE value decreased significantly at 1 week and 1 month (p = 0.002). The AVR value decreased significantly at 1 month (p = 0.028). CRVE values did not change at 1 week and 1 month (p = 0.083). In the bevacizumab group, the preinjection CRAE, CRVE, and AVR values did not change through the study period (p = 0.128, p = 0.600, and p = 0.734, respectively). Conclusion: These results suggest that intravitreal ranibizumab led to significant retinal arteriolar vasoconstriction in eyes with neovascular AMD.